Ces radiol. 2013, 67(1):52-58

Imaging of the carcinoid tumors using PET/CT with application of 18F-fluorodihydroxyphenylalanineOriginal article

Eva Ferdová1, Jiří Ferda1, Jan Baxa1, Jindřich Fínek2, Luboš Holubec jr.2, Tomáš Skalický3, Vladislav Třeška3, Boris Kreuzberg1
1 Klinika zobrazovacích metod LF UK a FN, Plzeň
2 Onkologické a radioterapeutické oddělení LF UK a FN, Plzeň
3 Chirurgická klinika LF UK a FN, Plzeň

Aim: To evaluate the a role of 18F-FDOPA-PET/CT in the imaging of neuroendocrine tumors (NET) of carcinoid type.

Method: The sample of 16 18F-FDOPA-PET/CT examinations was assessed in patients suffered from NET of carcinoid type. All examinations were performed after intravenous administration of 18F-fluorodihydroxyfenylalanine in the dose of 1-2 MBq per kilogram of body weight, when the full diagnostic dual-phase MDCT forms the integral part of the examination. The accumulation of the radiopharmaceutical was evaluated in primary tumor, liver metastases, bony metastases or infiltrated lymph nodes.

Results: Nine bowel carcinoids, three urogenital carcinoids, one lung carcinoid, one pancreatic polypeptidoma were investigated. Mean SUVmax reached 13.75 in liver metastases, in lymph nodes 23.38, and significantly differed from those measured in the background. The relation between applied radiopharmaceutical activity and maximum tumorous accumulation levels was not confirmed (p = 0.9195, correlation coefficient r = -0.03685).

Conclusion: 18F-FDOPA-PET/CT is useful tool in the evaluation of the spread of NET even if the primary tumor is not previously detected. In such cases, the primary tumor could be detected effectively. Also the assessment of the disease activity is possible.

Keywords: 18F-fluorodihydroxyphenylalanine, 18F-FDOPA, PET/CT, neuroendocrine tumors, carcinoid
Grants and funding:

Práce byla podpořena Programem rozvoje vědních oborů Karlovy Univerzity (projekt P36).

Accepted: February 15, 2013; Published: March 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferdová E, Ferda J, Baxa J, Fínek J, Holubec L, Skalický T, et al.. Imaging of the carcinoid tumors using PET/CT with application of 18F-fluorodihydroxyphenylalanine. Ces radiol. 2013;67(1):52-58.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wong KK, Waterfield RT, Marzola MC, et al. Contemporary nuclear medicine imaging of neuroendocrine tumours. Clin Radiol 2012; 67(11): 1035-1050. Go to original source... Go to PubMed...
    2. Chondrogiannis S, Grassetto G, Marzola MC, et al. 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours. Nucl Med Commun 2012; 33(2): 179-184. Go to original source... Go to PubMed...
    3. Ferda J, Ferdová E, Malán A, Záhlava J. Hybridní zobrazení SPECT/CT s 111IN-oktreotidem. Ces Radiol 2010; 64(4): 249-258.
    4. Minn H, Kauhanen S, Seppänen M, Nuutila P. 18F-FDOPA: a multiple-target molecule. J Nucl Med 2009; 50(12): 1915-1918. Go to original source... Go to PubMed...
    5. Yakemchuk VN, Jager PL, Chirakal R, et al. PET/CT using 18F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting. Nucl Med Commun 2012; 33(3): 322-330. Go to original source... Go to PubMed...
    6. Imperiale A, Rust E, Boulanger C, et al. Terminal ileum neuroendocrine incidentaloma in a patient with sporadic medullary thyroid carcinoma: findings from 18F-FDOPA PET/CT investigation. Clin Nucl Med 2012; 37(8): e206-8. doi: 10.1097/RLU.0b013e31824c5e04. Go to original source... Go to PubMed...
    7. Imperiale A, Taquet MC, Rust E, et al. Head-to-head comparison between SRS, (18)F-FDG and (18)F-FDOPA PET/CT in a patient with recurrent SDHC-related jugular paraganglioma. Eur J Nucl Med Mol Imaging 2012; 39(10): 1662-1663. Go to original source... Go to PubMed...
    8. Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot JN, Montravers F. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun 2012; 33(7): 775-779. doi: 10.1097/MNM.0b013e3283543304. Go to original source... Go to PubMed...
    9. Becherer A, Szabó M, Karanikas G, et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med 2004; 45(7): 1161-1167.

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content